Letter to the Editor
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. May 24, 2022; 13(5): 412-416
Published online May 24, 2022. doi: 10.5306/wjco.v13.i5.412
Commentary: Evaluating potential glioma serum biomarkers, with future applications
Michael Goutnik, Brandon Lucke-Wold
Michael Goutnik, Brandon Lucke-Wold, Department of Neurosurgery, University of Florida, Gainesville, FL 32608, United States
Author contributions: Goutnik M wrote the manuscript; Lucke-Wold B contributed to writing, and edited the manuscript.
Conflict-of-interest statement: The authors deny any conflicts of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Michael Goutnik, MS, Department of Neurosurgery, University of Florida, 1505 SW Archer Rd, Gainesville, FL 32608, United States. mgoutnik@ufl.edu
Received: November 28, 2021
Peer-review started: November 28, 2021
First decision: February 15, 2022
Revised: March 15, 2022
Accepted: May 14, 2022
Article in press: May 14, 2022
Published online: May 24, 2022
Processing time: 176 Days and 19.7 Hours
Core Tip

Core Tip: Systemic inflammation in malignant glioma, along with the potential for blood-based biomarkers, is an exciting field of ongoing research. We have discussed supporting and contrasting evidence for glioma blood-based biomarkers, along with future research proposals.